141 related articles for article (PubMed ID: 36123181)
21. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
Holland EA; Schmid H; Kefford RF; Mann GJ
Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
[TBL] [Abstract][Full Text] [Related]
22. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
[TBL] [Abstract][Full Text] [Related]
23. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors.
Piepkorn M
J Am Acad Dermatol; 2000 May; 42(5 Pt 1):705-22; quiz 723-6. PubMed ID: 10775844
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
25. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
26. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.
Fan M; Pfeffer SR; Lynch HT; Cassidy P; Leachman S; Pfeffer LM; Kopelovich L
Oncotarget; 2013 Jan; 4(1):128-41. PubMed ID: 23371019
[TBL] [Abstract][Full Text] [Related]
27. Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas.
Cabanillas R; Astudillo A; Valle M; de la Rosa J; Álvarez R; Durán NS; Cadiñanos J
Head Neck; 2013 Mar; 35(3):E80-4. PubMed ID: 22083977
[TBL] [Abstract][Full Text] [Related]
28. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
29. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
30. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
[TBL] [Abstract][Full Text] [Related]
31. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
32. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
33. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Sheppard KE; McArthur GA
Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
[TBL] [Abstract][Full Text] [Related]
34. Functional reassessment of P16 variants using a transfection-based assay.
Walker GJ; Gabrielli BG; Castellano M; Hayward NK
Int J Cancer; 1999 Jul; 82(2):305-12. PubMed ID: 10389768
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
Pasmant E; Laurendeau I; Héron D; Vidaud M; Vidaud D; Bièche I
Cancer Res; 2007 Apr; 67(8):3963-9. PubMed ID: 17440112
[TBL] [Abstract][Full Text] [Related]
36. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
37. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.
Mohseny AB; Tieken C; van der Velden PA; Szuhai K; de Andrea C; Hogendoorn PC; Cleton-Jansen AM
Genes Chromosomes Cancer; 2010 Dec; 49(12):1095-103. PubMed ID: 20737480
[TBL] [Abstract][Full Text] [Related]
38. [CDKN2A gene in melanoma].
Liu MT; Liu JY; Su J
Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):909-912. PubMed ID: 31775447
[TBL] [Abstract][Full Text] [Related]
39. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain.
Nagore E; Montoro A; Oltra S; Ledesma E; Botella-Estrada R; Millán JM; Oliver V; Fortea JM; Guillén C
Melanoma Res; 2005 Dec; 15(6):555-8. PubMed ID: 16314743
[No Abstract] [Full Text] [Related]
40. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
